Improved sexual function in male haemodialysis patients on bromocriptine.
The effect of bromocriptine on sexual activity was studied in male haemodialysis patients in a single-blind placebo controlled trial with random cross-over. At a dose of 2.5 mg bromocriptine twice day, plasma-prolactin concentrations were consistently reduced, while sexual function as assessed by a questionnaire was markedly improved. At the doses used, side-effects, particularly hypotension, were common, but bromocriptine helped to restore sexual function in dialysed patients.
D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D003075:Coitus; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007989:Libido / Q000187:drug effects*; D008297:Male; D010919:Placebos; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood; D011897:Random Allocation; D006435:Renal Dialysis / Q000009:adverse effects*
D010919:Placebos; D001971:Bromocriptine; D011388:Prolactin